当代医学
噹代醫學
당대의학
CHINA CONTEMPORARY MEDICINE
2013年
20期
2-4
,共3页
降脂治疗%糖耐量异常%高脂血症
降脂治療%糖耐量異常%高脂血癥
강지치료%당내량이상%고지혈증
Lipid-regulating%treatment Impaired glucose tolerance%Hyperlipemia
目的观察不同降脂治疗方案对糖耐量异常合并高脂血症的疗效及安全性。方法将168例糖耐量异常合并高脂血症的患者随机分为三组，即血脂康组，辛伐他汀组和生活方式干预组（对照组），治疗8个月后观察疗效。结果血脂康组及辛伐他汀组治疗8个月后TC、TG、LDL-C水平与治疗前对比有显著性降低，HDL-C显著升高（P<0.01），而对照组Tch、TG、LDL-C治疗后水平仅有轻度降低，HDL-C轻度升高（P﹥0.05）。血脂康组FBS、2 hPG及HbAIc与治疗前相比也有明显降低（P<0.05）；辛伐他汀组和对照组FBS、2 hPG及HbAIc与治疗前相比降低不明显（P﹥0.05）。结论血脂康更适合糖耐量异常合并高脂血症患者，能有效降低高脂血症及改善糖耐量异常，且安全性良好，值得在临床推广。
目的觀察不同降脂治療方案對糖耐量異常閤併高脂血癥的療效及安全性。方法將168例糖耐量異常閤併高脂血癥的患者隨機分為三組，即血脂康組，辛伐他汀組和生活方式榦預組（對照組），治療8箇月後觀察療效。結果血脂康組及辛伐他汀組治療8箇月後TC、TG、LDL-C水平與治療前對比有顯著性降低，HDL-C顯著升高（P<0.01），而對照組Tch、TG、LDL-C治療後水平僅有輕度降低，HDL-C輕度升高（P﹥0.05）。血脂康組FBS、2 hPG及HbAIc與治療前相比也有明顯降低（P<0.05）；辛伐他汀組和對照組FBS、2 hPG及HbAIc與治療前相比降低不明顯（P﹥0.05）。結論血脂康更適閤糖耐量異常閤併高脂血癥患者，能有效降低高脂血癥及改善糖耐量異常，且安全性良好，值得在臨床推廣。
목적관찰불동강지치료방안대당내량이상합병고지혈증적료효급안전성。방법장168례당내량이상합병고지혈증적환자수궤분위삼조，즉혈지강조，신벌타정조화생활방식간예조（대조조），치료8개월후관찰료효。결과혈지강조급신벌타정조치료8개월후TC、TG、LDL-C수평여치료전대비유현저성강저，HDL-C현저승고（P<0.01），이대조조Tch、TG、LDL-C치료후수평부유경도강저，HDL-C경도승고（P﹥0.05）。혈지강조FBS、2 hPG급HbAIc여치료전상비야유명현강저（P<0.05）；신벌타정조화대조조FBS、2 hPG급HbAIc여치료전상비강저불명현（P﹥0.05）。결론혈지강경괄합당내량이상합병고지혈증환자，능유효강저고지혈증급개선당내량이상，차안전성량호，치득재림상추엄。
Objective The study was conducted to investigate the clinical efifcacy and safety of different ways of lipid-modulating treatment for patients with impaired glucose tolerance and hyperlipemia. Methods 168 cases of patients with impaired glucose tolerance and hyperlipemia were randomly allocated to xuezhikang group , simvastatin group and lifestyle intervention group respectively . the therapeutic results were tested 8 months after treatment. Results After 8 months treatment , the lipid proifle was evidently improved in xuezhikang group and simvastatin group . level of total cholesterol ( TC ), triglyceridemia ( TG ) , low-density lipoprotein cholesterol ( LDL-C ) were signiifcantly reduced and high-density lipoprotein cholesterol ( HDL-C ) increased signiifcantly(P﹤0.01). Slightly change of above indicators were found in control group(P﹥0.05). The level of fasting plasma glucose ( FBS ) , 2 hours plasma glucose ( 2 hPG ) and glycohemoglobin ( HbAIc ) decreased obviously in xuezhikang group (P﹤0.05), while there were no obviously change of above-mentioned indices in both simvastatin group and lifestyle intervention group (P﹥0.05). Conclusion These results indicated that xuezhikang is effective in reducing hyperlipemia , improving impaired glucose tolerance , and it is safe . Therefore , xuezhikang is much more suitable for the treatment of patients with impaired glucose tolerance and hyperlipemia , it is worth to be widely used clinically .
